Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling

MLA

Wei-Jing Gong, et al. “Prediction of Response and Adverse Drug Reaction of Pemetrexed plus Platinum-Based Chemotherapy in Lung Adenocarcinoma by Serum Metabolomic Profiling.” Translational Oncology, vol. 19, no. 101393-, May 2022. EBSCOhost, https://doi.org/10.1016/j.tranon.2022.101393.

APA

Wei-Jing Gong, Peng Cao, Qi-Lin Zhang, Xiao-Yu Han, Shuo-Wen Wang, Yi-Fei Huang, San-Lan Wu, Qiang Li, Rui Zhang, Shuang-Bing Xu, Ya-Ni Liu, Shao-Jun Shi, & Yu Zhang. (2022). Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling. Translational Oncology, 19(101393-). https://doi.org/10.1016/j.tranon.2022.101393

Chicago

Wei-Jing Gong, Peng Cao, Qi-Lin Zhang, Xiao-Yu Han, Shuo-Wen Wang, Yi-Fei Huang, San-Lan Wu, et al. 2022. “Prediction of Response and Adverse Drug Reaction of Pemetrexed plus Platinum-Based Chemotherapy in Lung Adenocarcinoma by Serum Metabolomic Profiling.” Translational Oncology 19 (101393-). doi:10.1016/j.tranon.2022.101393.